Genovate Biotechnology Co (ROCO:4130) Piotroski F-Score: 6 (As of Jul. 14, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4130 Genovate Biotechnology Co Ltd ROCO:4130
72 GF Score
Price NT$26.85
GF Value NT$22.20
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Genovate Biotechnology Co Piotroski F-Score?

Genovate Biotechnology Co ROCO:4130 -4.62% 72 Piotroski F-Score is 6 as of Jul. 14, 2026, which is at its 10-year median of 6.00. GuruFocus rates ROCO:4130 with a GF Score™ of 72/100 and a GF Value™ of NT$22.20 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 1,333 Biotechnology companies, Genovate Biotechnology Co ranks better than 91.97% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Genovate Biotechnology Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Genovate Biotechnology Co's Piotroski F-Score or its related term are showing as below:

ROCO:4130' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 8
Current: 6

During the past 13 years, the highest Piotroski F-Score of Genovate Biotechnology Co was 8. The lowest was 3. And the median was 6.

Genovate Biotechnology Co  (ROCO:4130) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Genovate Biotechnology Co Piotroski F-Score Related Terms


Genovate Biotechnology Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Genovate Biotechnology Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genovate Biotechnology Co Piotroski F-Score Chart

Genovate Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 5.00 8.00 3.00 6.00

Genovate Biotechnology Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 4.00 5.00 5.00 6.00

ROCO:4130 vs VRTX, REGN, ALNY: Piotroski F-Score Comparison

For the Biotechnology subindustry, Genovate Biotechnology Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genovate Biotechnology Co Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genovate Biotechnology Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Genovate Biotechnology Co's Piotroski F-Score falls into.


ROCO:4130
72GF Score
Genovate Biotechnology Co Ltd ROCO:4130
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was 9.545 + 7.34 + -1.471 + -3.732 = NT$11.7 Mil.
Cash Flow from Operations was 41.224 + -26.501 + 12.136 + 16.93 = NT$43.8 Mil.
Revenue was 131.306 + 126.172 + 115.527 + 119.401 = NT$492.4 Mil.
Gross Profit was 47.303 + 48.315 + 40.81 + 40.594 = NT$177.0 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was
(1590.214 + 1590.264 + 1529.558 + 1498.758 + 1506.369) / 5 = NT$1543.0326 Mil.
Total Assets at the begining of this year (Dec24) was NT$1,590.2 Mil.
Long-Term Debt & Capital Lease Obligation was NT$0.6 Mil.
Total Current Assets was NT$719.3 Mil.
Total Current Liabilities was NT$125.3 Mil.
Net Income was 16.638 + 7.991 + 5.557 + -4.488 = NT$25.7 Mil.

Revenue was 139.359 + 126.9 + 126.376 + 118.221 = NT$510.9 Mil.
Gross Profit was 56.097 + 50.228 + 47.246 + 39.078 = NT$192.6 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was
(1600.456 + 1627.814 + 1649.058 + 1617.225 + 1590.214) / 5 = NT$1616.9534 Mil.
Total Assets at the begining of last year (Dec23) was NT$1,600.5 Mil.
Long-Term Debt & Capital Lease Obligation was NT$1.7 Mil.
Total Current Assets was NT$765.5 Mil.
Total Current Liabilities was NT$136.5 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Genovate Biotechnology Co's current Net Income (TTM) was 11.7. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Genovate Biotechnology Co's current Cash Flow from Operations (TTM) was 43.8. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=11.682/1590.214
=0.00734618

ROA (Last Year)=Net Income/Total Assets (Dec23)
=25.698/1600.456
=0.01605667

Genovate Biotechnology Co's return on assets of this year was 0.00734618. Genovate Biotechnology Co's return on assets of last year was 0.01605667. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Genovate Biotechnology Co's current Net Income (TTM) was 11.7. Genovate Biotechnology Co's current Cash Flow from Operations (TTM) was 43.8. ==> 43.8 > 11.7 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=0.607/1543.0326
=0.00039338

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=1.728/1616.9534
=0.00106868

Genovate Biotechnology Co's gearing of this year was 0.00039338. Genovate Biotechnology Co's gearing of last year was 0.00106868. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=719.298/125.322
=5.73959879

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=765.452/136.48
=5.60852872

Genovate Biotechnology Co's current ratio of this year was 5.73959879. Genovate Biotechnology Co's current ratio of last year was 5.60852872. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Genovate Biotechnology Co's number of shares in issue this year was 117.448. Genovate Biotechnology Co's number of shares in issue last year was 124.564. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=177.022/492.406
=0.35950415

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=192.649/510.856
=0.37711018

Genovate Biotechnology Co's gross margin of this year was 0.35950415. Genovate Biotechnology Co's gross margin of last year was 0.37711018. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=492.406/1590.214
=0.30964763

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=510.856/1600.456
=0.31919403

Genovate Biotechnology Co's asset turnover of this year was 0.30964763. Genovate Biotechnology Co's asset turnover of last year was 0.31919403. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+1+1+0+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Genovate Biotechnology Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Genovate Biotechnology Co (ROCO:4130) has a Piotroski F-Score of 6 as of Jul. 14, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Genovate Biotechnology Co and its competitors. This is near median its historical median of 6.00. Over the past decade, Genovate Biotechnology Co's Piotroski F-Score has ranged from 3.00 to 8.00. According to the industry distribution chart, Genovate Biotechnology Co ranks #107 out of 1333 companies in the Biotechnology industry, placing it in the top 8%.
Is Genovate Biotechnology Co's Piotroski F-Score too high?
Genovate Biotechnology Co's current Piotroski F-Score of 6 is near median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 8.00. The Biotechnology industry median Piotroski F-Score is 3.00. Genovate Biotechnology Co's value of 6 is 100% above this industry median. Based on the distribution chart, Genovate Biotechnology Co ranks #107 out of 1333 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genovate Biotechnology Co has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genovate Biotechnology Co's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genovate Biotechnology Co ranks #107 out of 1333 companies for Piotroski F-Score. This places Genovate Biotechnology Co in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Genovate Biotechnology Co's value of 6 is 100% above this benchmark. Historically, Genovate Biotechnology Co's own Piotroski F-Score has ranged from 3.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 3.00, Genovate Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,333 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genovate Biotechnology Co's current Piotroski F-Score of 6 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Genovate Biotechnology Co and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genovate Biotechnology Co's current Piotroski F-Score is 6, which is near median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovate Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Genovate Biotechnology Co (ROCO:4130) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$22.20, compared to a current price of NT$26.85 — trading 20.9% above its estimated fair value. The current Piotroski F-Score is 6, which is near median its 10-year median of 6.00 and 100% above the Biotechnology industry median of 3.00. Genovate Biotechnology Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Genovate Biotechnology Co (ROCO:4130), the current Piotroski F-Score is 6 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genovate Biotechnology Co (ROCO:4130) Overvalued in 2026?

Based on GuruFocus' analysis, Genovate Biotechnology Co stock appears to be overvalued. The current stock price of NT$26.85 is trading 20.9% above its estimated GF Value™ of NT$22.20. GuruFocus considers Genovate Biotechnology Co to be Modestly Overvalued.

Key valuation signals for ROCO:4130:

  • Piotroski F-Score: 6 (near median its 10-year median of 6.00)
  • GF Value™: NT$22.20 vs. price of NT$26.85 (20.9% above fair value)
  • GF Score™: 72/100 with 3 warning signs
  • Industry Position: 100% above the Biotechnology median (#107 of 1333)

No single metric tells the full story. See the ROCO:4130 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genovate Biotechnology Co Business Description

Address No.1, First Industrial Road, Hsin-Chu Expanded Park, Hukou Township, Guangdong Province, Hsin-Chu county, Hsin-Chu, TWN, 303036
Genovate Biotechnology Co Ltd develops, produces, manufactures, and sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases, etc. The company is also engaged in the sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases etc.
72GF Score

Get the complete analysis for ROCO:4130

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$26.85
Price
NT$22.20
GF Value